Needham & Company Upgrades Achaogen (AKAO) to Buy

Achaogen (AKAO) Sees Red-to-Green Reversal

Achaogen (NASDAQ: AKAO) sees strong red-to-green reversal after pricing its equity offering at $13.50. Shares were last up 0.5% to $14.94.

Shares have surged over the past two session amid positive trial data.

Achaogen (AKAO) Bucks Stock Offering Weakness Amid Bullish Analyst Predictions

After gaining 148% on Monday amid positive trial results, Achaogen (NASDAQ: AKAO) is up another 13% in pre-open trade Tuesday despite announcing a public offering of up to 5,750,000 shares of its common stock.

The stock appears to be keying off an... More

Achaogen (AKAO) PT Raised to $25 at William Blair

William Blair analyst Y. Katherine Xu reiterated an Outperform rating and raised her price target on Achaogen (NASDAQ: AKAO) to $25.00 (from $11.00) reported positive top-line results from the Phase III registrational studies, which exceeded expectations.

Xu commented, "EPIC demonstrated superiority for plazomicin on three of four co-primary endpoints as... More

Achaogen (AKAO) Commences 5.75M Offering of Common Stock

Achaogen, Inc. (NASDAQ: AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to 5,750,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market... More

Achaogen (AKAO) Adds to Gains, Shares up 75%

Achaogen (NASDAQ: AKAO) pushes to the high of the session following earlier positive data. Shares are up 75% on volume that is 213x normal.

Achaogen's (AKAO) Phase 3 cUTI and CRE Trial of Plazomicin Achieves Primary Endpoints

Achaogen, Inc. (NASDAQ: AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that its lead product candidate, plazomicin, met the objective of non-inferiority compared to meropenem for the U.S. Food and Drug Administration (FDA) and achieved superiority for the European Medicines Agency (EMA) primary efficacy endpoints in the Phase 3 EPIC registration trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In addition, in the Phase 3 CARE trial in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) a lower rate of mortality or serious... More